Fluoropyrimidine Therapy in Gastrointestinal Cancer
Open Access
- 9 April 2025
- journal article
- editorial
- Published by Elsevier in JACC: Cardiooncology
- Vol. 7 (4) , 357-359
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysisBMC Cancer, 2024
- Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)Acta Oncologica, 2024
- Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancerESMO Open, 2023
- The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasmPLOS ONE, 2022
- Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular diseaseJournal of Molecular and Cellular Cardiology, 2021
- The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary VasospasmJACC: Cardiooncology, 2021
- How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest PainJACC: Cardiooncology, 2020
- Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or CapecitabineClinical Colorectal Cancer, 2019
- 5-fluorouracil and cardiotoxicity: a reviewTherapeutic Advances in Medical Oncology, 2018
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular DiseaseNew England Journal of Medicine, 2017